ALOFT-068 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
You may be eligible if you:
– ≥ 40 years of age
– Received a diagnosis of IPF within the last 7 years
– Non-smoking status
WHISTLE-PF – A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis
You may be eligible if you:
– ≥ 40 years of age
– Received a diagnosis of IPF within the last 5 years
– Non-smoking status
ALOFT-1015 – A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
You may be eligible if you:
– ≥ 21 years of age
– Received a diagnosis of interstitial lung disease in the last two years
– Non-smoking status
RIN-PF-304 – A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis
You may be eligible if you:
– ≥ 18 years of age
– Diagnosis of PPF within the last 2 years
FLAIR – A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed Dose Combination on Severe Asthma Exacerbations in Patients with Asthma
You may be eligible if you:
– ≥ 18 years of age
– Diagnosis of asthma for at least 1 year
– At least one severe clinical asthma exacerbations
– Never smoked or ex smoker with <10 pack years history
INBRX101-01-202 – A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of INBRX-101 in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
You may be eligible if you:
– ≥ 18 years of age
– Diagnosis of AATD
– Diagnosis of emphysema within the last 2 years
– Non-smoking status
AER-01-002 – A Phase 2a, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fexlamose (AER-01) Inhalation Solution in the Treatment of Adults with Moderate to Severe Chronic Obstructive Pulmonary Disease
You may be eligible if you:
– ≥40 to ≤80 years of age
– Verified diagnosis of cigarette smoking-related COPD
Chronic Spontaneous Urticaria:
CDX0159-13 – A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
You may be eligible if you:
– ≥ 18 years of age
– Diagnosis of Chronic Spontaneous Urticaria ≥ 6 months prior
ASAR – The ASAR is a multicentre cross-sectional study of the characteristics of severe asthma, based around asthma phenotypes, and a prospective cohort study of the outcomes and future risks of phenotypes of severe asthma. The ASAR will deliver systematic monitoring of the suitability and effectiveness of health care in severe asthma patients, by routinely (annually) collecting, analysing and reporting on severe asthma-related information. This project enables data collection in the Australasian region for severe asthma.
You may be eligible if you:
– ≥ 18 years of age
– Have a confirmed asthma diagnosis with variable airflow obstruction and is uncontrolled
Your involvement includes:
Annual follow ups for 10 years where we will collate data from questionnaires and your medical history.
ALST – The Australian Lung Screen Trial (ALST) focuses on never or light smokers who traditionally do not meet current screening eligibility criteria but are at higher risk of lung cancer. Participants that meet the criteria will undergo a chest CT scan and will be followed up for 10 years where they will be invited to complete questionnaires on potential incidental findings.
You may be eligible if you:
– ≥55 to ≤74 years of age
– Never smokers, current light smokers, or former light smokers.
Your involvement includes:
– Attending one or more CT scans
– Completing some questionnaires
AILDR – The Australasian Interstitial Lung Disease Registry aims to provide a valuable resource for high quality Interstitial Lung Disease (ILD) research and improve care for ILD patients across Australia and New Zealand. The registry captures longitudinal data relating to the causes, exposures, disease types and behaviour, associated morbidity and mortality, patterns of care, and healthcare resource utilisation.
You may be eligible if you:
– ≥ 18 years old
– Diagnosis of an ILD